PharmaShots | Incisive News in 3 Shots

Subscribe Now

AbbVie

$AbbVie and Genmab Receive EC’s Conditional Marketing for Tepkinly (epcoritamab) to Treat Relapsed or Refractory Diffuse Large B-cell Lymphoma$

AbbVie and Genmab Receive EC’s Conditional Marketing for Tepkinly (epcoritamab) to Treat Relapsed or Refractory Diffuse Large B-ce...

September 26, 2023

AbbVie Terminates the Development and Option Agreement with Harpoon Therapeutics for HPN217

AbbVie Terminates the Development and Option Agreement with Harpoon Therapeutics for HPN217

September 14, 2023

AbbVie’s Skyrizi (risankizumab) Meet Primary and Secondary Endpoints in P-III (SEQUENCE) Head-to-Head Study for Crohn's Disease

AbbVie’s Skyrizi (risankizumab) Meet Primary and Secondary Endpoints in P-III (SEQUENCE) Head-to-Head Study for Crohn's Disease

September 13, 2023

AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults

AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults

September 4, 2023

AbbVie’s Aquipta (atogepant) Receives EC’s Approval for the Preventive Treatment of Migraine in Adults

AbbVie’s Aquipta (atogepant) Receives EC’s Approval for the Preventive Treatment of Migraine in Adults

August 17, 2023

AbbVie Reports P-IV (IMMpulse) Study Results of Skyrizi (risankizumab) for Adult Patients with Moderate Plaque Psoriasis

AbbVie Reports P-IV (IMMpulse) Study Results of Skyrizi (risankizumab) for Adult Patients with Moderate Plaque Psoriasis

July 27, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us